Antimicrobial photonic technology: Arlumen participates in a targeted therapy project with INSERM

3 March 0023

Using Light to Activate Lung Treatment In Vivo: A Closer Look at Arlumen’s (formerly Evosens) Collaboration on INSERM’s TARGET THERAPY Antimicrobial Photodynamic Therapy Project

The target-therapy project

The ANR/BMBF-funded TARGET-THERAPY project is a bilateral collaboration (coordinated by Dr. Tony Le Gall in France and Professor Dr. Holger Schönherr in Germany), bringing together research teams with expertise in chemistry, biology and medicine.

This project aims to significantly improve the treatment of recalcitrant bacterial infections of the respiratory tract, focusing on the World Health Organization's priority 1 pathogen, Pseudomonas aeruginosa, which is one of the most dangerous multi-drug resistant bacteria.

"Illumination under in vitro conditions is relatively easy to achieve, but much more difficult under in vivo conditions. In this case, it is essential to have a device that is not only effective but also qualified and approved, from a preclinical point of view. Ready-to-use solutions are available from specialist manufacturers, but they can be very expensive, not fully adapted to the intended use, and not easily adaptable or scalable," says Dr. Tony Le Gall.

photodynamic therapy

The therapeutic approach is based on photodynamic therapy, which shows great promise in combating the loss of efficacy of current antibiotics. It uses light-sensitive markers which, when exposed to light, cause oxidative damage that kills pathogens in their environment.

photosensitive therapy INSERM Arlumen
photosensitive therapy INSERM Arlumen

A specific protocol is being developed, taking into account the following steps: (i) use of specially designed photodynamic systems, (ii) delivery to the pulmonary tract by a clinically applicable method, and (iii) in situ activation by application of a localized light treatment.

As a result, the target bacteria can be eradicated in the complex environment of the respiratory tract. The protocol is designed to ensure both efficacy and safety, as well as to circumvent pre-existing bacterial resistance. To provide proof of concept for this approach, a key point is to have dedicated light illumination systems.

Arlumen's contribution to the INSERM project

Arlumen—formerly EVOSENS—is a leading photonics company specializing in the integration of optical systems, located in Plouzané, France. It is collaborating with INSERM on the TARGET-THERAPY project, contributing its expertise in the development of “customized” solutions tailored to the intended biomedical application. Arlumen—formerly EVOSENS—and the TARGET-THERAPY project team were brought together by Photonics Bretagne, a cluster of regional companies specializing in photonic technologies.

This partnership recently came to fruition in "ILightIT!", a BPGO-awarded project aimed specifically at helping to find lighting solutions to demonstrate - in ex vivo conditions and then on a murine animal model - the efficacy of the photodynamic systems developed as part of the TARGET-THERAPY project.

The specifications of an "ideal" fibered light device are manifold, including:

  • small size
  • no or low heating effect
  • emission at the absorption wavelength peak of the photosensitive markers
  • sufficient irradiance and power
  • scalability and upgradability (by adapting interchangeable modules, particularly for peak irradiation).

After several discussions, feasibility tests were conducted, taking into account various characteristics of the light-emitting tip, such as its material, diameter, flexibility, durability, and biocompatibility. In January 2023, Arlumen—formerly EVOSENS—provided INSERM with an initial device, which is currently being evaluated in various experimental settings.

In the longer term, an evolution of the illumination protocol may be envisaged, using a non-invasive illumination system capable of activating photodynamic systems of infectious sites deep inside the body.

T. Le Gall INSERM / Arlumen
https://nouveau.univ-brest.fr/target-therapy-project/en/actualite/evosens-company-target-therapy-project

Discover also

Optical imaging: capturing and observing images, from microns to light-years

The Arlumen Photonics and Optics Summer Workbook!

Do you have a photonics project?